Table 3.

Association of clinical and pathologic characteristics with molecular abnormalities (combined AAM and CaM cohorts)

ERG rearrangementPTEN deletionSPINK1 overexpressionSPOP mutation
PositiveNegativePDeletedWild-typePPositiveNegativePMutatedWild-typeP
Age at surgery (mean ± SD)59.9 ± 7.060.7 ± 7.60.29864.6 ± 7.459.5 ± 7.30.00157.6 ± 8.260.9 ± 7.10.06760.8 ± 7.260.3 ± 7.40.812
BMI (mean ± SD)26.9 ± 3.227.0 ± 4.80.62226.4 ± 2.327.1 ± 4.60.62826.0 ± 3.327.1 ± 4.50.19027.0 ± 4.726.5 ± 3.80.899
Gleason score [no./total (%)]0.285<0.0010.1630.305
 613/37(35)24/37(65)1/35(3)34/35(97)9/36(25)27/36(75)0/29(0)29/29(100)
 7(3 + 4)48/120(40)72/120(60)12/109(11)97/109(89)20/118(17)98/118(83)7/96(7)89/96(93)
 7(4 + 3)9/39(23)30/39(77)5/35(14)30/35(66)4/39(10)35/39(90)4/34(12)30/34(88)
 8 and 97/22(32)15/22(68)8/18(44)10/18(56)1/22(5)21/22(95)1/19(5)18/19(95)
Pathologic stage [no./total (%)]0.1390.0031.0000.259
 T259/165 (35.8)106/165 (64.2)13/149 (8.7)136/149 (91.3)26/162 (16.0)136/162 (84.0)11/123 (8.9)112/123 (91.1)
 T3a16/38 (42.1)22/38 (57.9)8/33 (24.2)25/33 (75.8)6/38 (15.8)32/38 (84.2)0/28(0)28/28 (100)
 T3b2/15 (13.3)13/15 (86.7)5/15 (33.3)10/15 (66.7)2/15 (13.3)13/15 (86.7)1/14 (7.1)13/14 (92.9)
Margin positivity [no./total (%)]8/218 (3.7)23/218 (10.5)0.3112/197 (1.0)25/197 (12.7)0.5414/215 (1.9)27/215 (12.6)0.7931/166 (0.6)26/166 (15.7)0.440
Biochemical recurrence [no./total (%)]7/191 (3.6)19/191 (9.9)0.3837/171 (4.0)16/171 (9.3)0.0245/188 (2.6)21/188 (11.1)0.5622/141 (1.4)21/141 (14.9)0.743